Weekly shot could help shed pounds in obesity trial
NCT ID NCT07690826
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This phase 2 study tests HRS-4729, a once-weekly injection, for weight loss in adults with obesity who do not have diabetes. About 252 participants will receive either the drug or a placebo. The main goal is to see how much body weight changes after 32 weeks compared to a placebo group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HRS-4729 injection
- What this could lead to
- If successful, this could offer a new once-weekly injection to help people with obesity lose significant weight.
- What could go wrong
- This is an early phase 2 trial, so the drug may not prove effective or safe enough for wider use. Side effects are possible, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 252 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Able and willing to provide a written informed consent. 2. Male or female adults aged 18 to 65 years. 3. BMI: 28.0 to 40.0 kg/m2. 4. Self-reported diet and exercise control for at least 3 months before screening, with body weight change of no more than 5 kg during the previous 3 months. Exclusion Criteria: 1. Endocrine disease or history that may have a significant effect on body weight; 2. History of diabetes mellitus (gestational diabetes excepted); 3. Malignancy of any organ system within the past 5 years, irrespective of evidence of local recurrence or metastasis, except for adequately treated localized basal cell carcinoma of the skin, carcinoma in situ of the cervix, and prostate carcinoma in situ; 4. Presence or suspicion of depression, anxiety disorder, bipolar disorder, suicidal ideation, schizophrenia, or other clinically significant psychiatric disorder, or a history of suicide attempt; 5. Known or suspected excessive alcohol use, or a history of alcohol, drug, or substance abuse; 6. Acute or chronic hepatitis, or a history of severe hepatic disease other than metabolic dysfunction-associated fatty liver disease; 7. Prior or planned organ or bone marrow transplantation during the study period; 8. Any hematologic disorder that may interfere with the determination of HbA1c; 9. An autoimmune disease for which systemic corticosteroid or immunosuppressive therapy is planned during the study period; 10. Use of any medication or treatment likely to cause clinically significant weight gain or weight loss within 3 months prior to screening; 11. Participation in any clinical trial of an investigational drug or medical device within 3 months prior to screening; 12. Blood donation or blood loss ≥400 mL, or receipt of a blood transfusion, within 3 months prior to screening; 13. Mental incapacity or language impairment sufficient to preclude adequate understanding of, or participation in, the trial procedures; 14. Investigators, site staff, or other personnel directly involved in conduct of the study, and their immediate family members; employees of the Sponsor; 15. Any condition that, in the investigator's judgment, would compromise participant safety or otherwise interfere with the assessment of study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental injection help people with obesity shed pounds?
- A cup of beans a day: could it calm inflammation and boost insulin response?
- Can a new pill help fight obesity? a trial puts HRS-7535 to the test
- Could shedding pounds be the key to silencing chronic back pain?
- Could a new injection help tackle obesity? a safety trial begins
- Can a new injection help tackle obesity and diabetes? a safety trial begins